Literature DB >> 29259002

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Amer M Zeidan1,2, Maximilian Stahl1,2, Xin Hu2, Rong Wang2,3, Scott F Huntington1,2, Nikolai A Podoltsev1,2, Steven D Gore1,2, Xiaomei Ma2,3, Amy J Davidoff2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29259002      PMCID： PMC6410557          DOI： 10.1182/blood-2017-10-811729

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Authors:  Amer M Zeidan; Rong Wang; Cary P Gross; Steven D Gore; Scott F Huntington; Thomas Prebet; Gregory A Abel; Amy J Davidoff; Xiaomei Ma
Journal:  Leuk Lymphoma       Date:  2016-08-25

2.  Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Authors:  A M Zeidan; M A Sekeres; G Garcia-Manero; D P Steensma; K Zell; J Barnard; N A Ali; C Zimmerman; G Roboz; A DeZern; A Nazha; E Jabbour; H Kantarjian; S D Gore; J P Maciejewski; A List; R Komrokji
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

Review 3.  Myelodysplastic Syndromes: Diagnosis and Treatment.

Authors:  David P Steensma
Journal:  Mayo Clin Proc       Date:  2015-07       Impact factor: 7.616

4.  Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Authors:  T Bernal; P Martínez-Camblor; J Sánchez-García; R de Paz; E Luño; B Nomdedeu; M T Ardanaz; C Pedro; M L Amigo; B Xicoy; C del Cañizo; M Tormo; J Bargay; D Valcárcel; S Brunet; L Benlloch; G Sanz
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

Review 5.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

6.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

Review 7.  Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights.

Authors:  Uwe Platzbecker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

8.  Underreporting of myeloid malignancies by United States cancer registries.

Authors:  Benjamin M Craig; Dana E Rollison; Alan F List; Christopher R Cogle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-11       Impact factor: 4.254

9.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors:  Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

10.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860
View more
  12 in total

1.  Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†.

Authors:  Amy J Davidoff; Xin Hu; Jan Philipp Bewersdorf; Rong Wang; Nikolai A Podoltsev; Scott F Huntington; Steven D Gore; Xiaomei Ma; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2019-12-26

Review 2.  Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?

Authors:  Marie Robin; Pierre Fenaux
Journal:  Leukemia       Date:  2020-07-13       Impact factor: 11.528

Review 3.  Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2020-05-18

Review 4.  Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.

Authors:  Anand A Patel; Kirk Cahill; Caner Saygin; Olatoyosi Odenike
Journal:  Blood Adv       Date:  2021-04-27

5.  Oral hypomethylating agents: beyond convenience in MDS.

Authors:  Elizabeth A Griffiths
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.

Authors:  Xiao Li; Feng Xu; Zheng Zhang; Juan Guo; Qi He; Lu-Xi Song; Dong Wu; Li-Yu Zhou; Ji-Ying Su; Chao Xiao; Chun-Kang Chang; Ling-Yun Wu
Journal:  Clin Epigenetics       Date:  2021-08-30       Impact factor: 6.551

7.  Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?

Authors:  Andrew M Brunner; Geoffrey Fell; David P Steensma
Journal:  Blood Adv       Date:  2022-05-10

Review 8.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923

9.  Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Authors:  Amer M Zeidan; Maximilian Stahl; Michelle DeVeaux; Smith Giri; Scott Huntington; Nikolai Podoltsev; Rong Wang; Xiaomei Ma; Amy J Davidoff; Steven D Gore
Journal:  Blood Cancer J       Date:  2018-06-11       Impact factor: 11.037

10.  [Efficacy and safety of generic azacitidine in Chinese patients with higher-risk myelodysplastic syndromes: a multicenter, prospective, single-arm study].

Authors:  H G Zhao; F Liu; T J Qin; H Bai; M Hou; K Yu; Y Hu; L Liu; Y Li; L Yu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.